Kite targets HPV-related cancers with TCR deal; Emergent Bio licenses Ligand's antibody tech;

@FierceBiotech: BU group spotlights a lethal cascade that leads to Parkinson's. FierceBiotechResearch story | Follow @FierceBiotech

@JohnCFierce: When has Pfizer ever won an R&D marathon in the last decade? | Follow @JohnCFierce

> Kite Pharma ($KITE), developing immunotherapies for cancer, signed a deal with the Netherlands' Leiden University Medical Center to collaborate on T cell receptor treatments for solid tumors related to HPV. More

> Emergent BioSolutions ($EBS) licensed Ligand Pharmaceuticals' ($LGND) R&D technology in hopes of crafting new antibody therapies. Item

> DelMar Pharmaceuticals is partnering with the University of Texas' MD Anderson Cancer Center to accelerate the development of its VAL-083 in brain cancer. News

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic earns CE mark to use its drug-eluting balloon to help hemodialysis patients. Article | Follow @FierceMedDev

@EmilyWFierce: Zoetis slammed with up to $45M charge after EU ruling on Belgian tax scheme. FierceAnimalHealth story | Follow @EmilyWFierce

> In a win for LivaNova, the FDA approves the world's only sutureless aortic valve. Article

Pharma News

@FiercePharma: Will pharma marketing to Hispanics finally gain traction in 2016? FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: Bayer's new plant in China will make both traditional Chinese meds and western OTC meds. FiercePharmaManufacturing report | Follow @EricPFierce

> Shire CEO thinks he can beat $500M in post-merger cost savings. More

> Depomed isn't anti-takeover, CEO says. It was just anti-Horizon. Article

Pharma Marketing News

> Will pharma marketing to Hispanics finally gain traction in 2016? More

> To flip the pricing debate, Big Pharma needs to tell some secrets. Story

> Look out, CLL. AbbVie and Roche's new venetoclax is on FDA's priority track. More

> Can Shire make the most of Baxalta's hemophilia meds? Item

> GSK's Slaoui sees 'major' vaccine market disruption for Merck as shingles candidate progresses. Article

Biotech Research News

> Cold Spring Harbor scientists develop a new drug for breast cancer. Report

> Johns Hopkins flags another possible successor to 'Special K' for depression. Story

> BU group spotlights a lethal cascade that leads to Parkinson's. More

> Slashing p75 neurotrophin receptor reduces obesity in mice: Gladstone. Article

> EPFL team creates an industrial-scale platform for stem cells. Item

Vaccines News

> Nearly a year into Novartis integration, GSK CEO won't discount vaccines spinoff. Report

> Aimmune takes peanut allergy vaccine into PhIII. More

> WHO seeks to ease cholera vaccine shortage with EuBiologics approval. Story

> Deal in Russia could cause Pfizer, GSK to lose contracts. Item

> New HIV vaccine player Aelix Therapeutics hits the scene with $12.7M Series A. Article

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.